Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Recurrence 1Neoplasm, Residual 1Multiple Myeloma 1

Interventions

Cyclophosphamide 4blinatumomab 3Azacitidine 3venetoclax 2tetrathiomolybdate 1tagraxofusp 1siremadlin 1sabatolimab 1posaconazole 1pembrolizumab 1midostaurin 1fludarabine phosphate 1fludarabine 1daratumumab 1avelumab 1aflutinib 1Whole-Body Irradiation 1Sirolimus 1Mycophenolic Acid 1Monatide (IMS 3015) 1Midazolam 1Melphalan 1Injections 1Idarubicin 1Daunorubicin 1Cytarabine 1Celecoxib 1Capecitabine 1Biological Assay 1Anthracyclines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasm, Residual × tetrathiomolybdate × Clear all
NCT06134375 2026-04-20

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Dartmouth-Hitchcock Medical Center

Phase 1/2 Recruiting
204 enrolled
Breast

Neoplasm, Residual, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡